[{"id":"62ace1f9-004a-49d4-93f7-a7a0fc5fb5bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02531932","created_at":"2021-02-22T06:52:40.461Z","updated_at":"2025-02-25T14:00:45.845Z","phase":"Phase 2","brief_title":"Comparison of Single-Agent Carboplatin Vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer","source_id_and_acronym":"NCT02531932","lead_sponsor":"Amy Tiersten","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • everolimus"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 12/16/2015","start_date":" 12/16/2015","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 10/19/2024","study_completion_date":" 10/19/2024","last_update_posted":"2025-02-19"},{"id":"59d4a003-e862-4682-ad7b-ffa3cb7e3e25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190174","created_at":"2021-01-18T15:43:45.733Z","updated_at":"2025-02-25T14:15:01.560Z","phase":"Phase 1/2","brief_title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","source_id_and_acronym":"NCT03190174","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2017","start_date":" 08/24/2017","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/02/2021","study_completion_date":" 12/02/2021","last_update_posted":"2025-02-17"},{"id":"111dadaf-4e0e-41c4-96f3-ff25aabf637a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03047213","created_at":"2021-01-18T15:00:26.479Z","updated_at":"2025-02-25T15:17:24.811Z","phase":"Phase 2","brief_title":"Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations","source_id_and_acronym":"NCT03047213","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TSC2 • TSC1","pipe":" | ","alterations":" TSC1 mutation • TSC2 mutation","tags":["TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 08/24/2017","start_date":" 08/24/2017","primary_txt":" Primary completion: 10/06/2020","primary_completion_date":" 10/06/2020","study_txt":" Completion: 11/11/2025","study_completion_date":" 11/11/2025","last_update_posted":"2025-02-12"},{"id":"7f3a4417-d9e1-41f2-85e6-183300a2b151","acronym":"NCI-2017-01311","url":"https://clinicaltrials.gov/study/NCT03246906","created_at":"2021-01-18T16:02:34.370Z","updated_at":"2025-02-25T16:44:11.978Z","phase":"Phase 2","brief_title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","source_id_and_acronym":"NCT03246906 - NCI-2017-01311","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/11/2017","start_date":" 09/11/2017","primary_txt":" Primary completion: 05/03/2025","primary_completion_date":" 05/03/2025","study_txt":" Completion: 05/03/2025","study_completion_date":" 05/03/2025","last_update_posted":"2025-02-05"},{"id":"b5993f06-cb2c-4080-9676-30541427ea90","acronym":"","url":"https://clinicaltrials.gov/study/NCT00980460","created_at":"2021-01-18T03:49:34.064Z","updated_at":"2025-02-25T16:50:58.740Z","phase":"Phase 3","brief_title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","source_id_and_acronym":"NCT00980460","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • doxorubicin hydrochloride • irinotecan • temsirolimus • vincristine • fluorouracil topical • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 236","initiation":"Initiation: 09/14/2009","start_date":" 09/14/2009","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2025-02-04"},{"id":"d16edb9e-05b0-4a67-8757-e2748c115c02","acronym":"ARST1431","url":"https://clinicaltrials.gov/study/NCT02567435","created_at":"2024-01-09T20:20:40.495Z","updated_at":"2025-02-25T16:51:34.054Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","source_id_and_acronym":"NCT02567435 - ARST1431","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FOXO1 • PAX3 • PAX7","pipe":"","alterations":" ","tags":["FOXO1 • PAX3 • PAX7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • irinotecan • temsirolimus • vincristine • vinorelbine tartrate • dactinomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 325","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 10/16/2025","study_completion_date":" 10/16/2025","last_update_posted":"2025-02-04"},{"id":"2cfcde7a-d491-42b2-9d06-8123de42c77d","acronym":"A091302","url":"https://clinicaltrials.gov/study/NCT02143726","created_at":"2021-09-08T20:53:26.218Z","updated_at":"2025-02-25T15:41:37.517Z","phase":"Phase 2","brief_title":"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer","source_id_and_acronym":"NCT02143726 - A091302","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/09/2014","start_date":" 10/09/2014","primary_txt":" Primary completion: 01/28/2021","primary_completion_date":" 01/28/2021","study_txt":" Completion: 08/06/2028","study_completion_date":" 08/06/2028","last_update_posted":"2025-01-27"},{"id":"fe616f09-6291-4f55-8056-8b008452edb9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06757634","created_at":"2025-02-25T20:04:40.854Z","updated_at":"2025-02-25T20:04:40.854Z","phase":"Phase 3","brief_title":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","source_id_and_acronym":"NCT06757634","lead_sponsor":"Celcuity Inc","biomarkers":" PIK3CA","pipe":"","alterations":" ","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Kisqali (ribociclib) • fulvestrant • gedatolisib (PF-05212384)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 674","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-01-07"},{"id":"1fa5498c-1aea-4d87-9474-f28a1ded3063","acronym":"MANTA","url":"https://clinicaltrials.gov/study/NCT02216786","created_at":"2021-01-18T10:23:25.940Z","updated_at":"2025-02-25T15:06:06.929Z","phase":"Phase 2","brief_title":"A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer","source_id_and_acronym":"NCT02216786 - MANTA","lead_sponsor":"Queen Mary University of London","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • fulvestrant • vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 333","initiation":"Initiation: 01/16/2014","start_date":" 01/16/2014","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2024-12-02"},{"id":"61d86a30-55c7-41a4-bec4-37a547f93c03","acronym":"OP-1250-003","url":"https://clinicaltrials.gov/study/NCT05508906","created_at":"2022-08-19T17:10:19.756Z","updated_at":"2025-02-25T15:54:36.272Z","phase":"Phase 1","brief_title":"Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus","source_id_and_acronym":"NCT05508906 - OP-1250-003","lead_sponsor":"Olema Pharmaceuticals, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Piqray (alpelisib) • Kisqali (ribociclib) • palazestrant (OP-1250)"],"overall_status":"Recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 05/20/2026","primary_completion_date":" 05/20/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-10-03"},{"id":"072b5222-7280-4f30-8150-3b6f5d947d3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02228681","created_at":"2024-01-03T20:17:23.392Z","updated_at":"2025-02-25T15:41:52.541Z","phase":"Phase 2","brief_title":"Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer","source_id_and_acronym":"NCT02228681","lead_sponsor":"GOG Foundation","biomarkers":" PIK3CA • PGR • PTEN • CTNNB1","pipe":" | ","alterations":" KRAS mutation • PIK3CA mutation","tags":["PIK3CA • PGR • PTEN • CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • tamoxifen • letrozole"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 05/21/2015","start_date":" 05/21/2015","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 08/22/2024","study_completion_date":" 08/22/2024","last_update_posted":"2024-09-19"},{"id":"12f81b1d-451f-4a1e-b774-333646268edd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05009992","created_at":"2024-06-15T04:08:56.168Z","updated_at":"2024-07-02T16:34:26.237Z","phase":"Phase 2","brief_title":"Combination Therapy for the Treatment of Diffuse Midline Gliomas","source_id_and_acronym":"NCT05009992","lead_sponsor":"University of California, San Francisco","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone) • paxalisib (GDC-0084)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 10/20/2021","start_date":" 10/20/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2024-06-13"},{"id":"6c1bf2f9-a643-4b80-84fa-1e32b26a8869","acronym":"BTCRC-BRE18-337","url":"https://clinicaltrials.gov/study/NCT03911973","created_at":"2021-01-18T19:15:11.647Z","updated_at":"2024-07-02T16:34:37.336Z","phase":"Phase 1/2","brief_title":"Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers","source_id_and_acronym":"NCT03911973 - BTCRC-BRE18-337","lead_sponsor":"Kari Wisinski","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA1 negative","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • gedatolisib (PF-05212384)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 04/17/2019","start_date":" 04/17/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-07"},{"id":"5cc7ea58-5792-4936-b0c7-76d10e021a5b","acronym":"PASTOR","url":"https://clinicaltrials.gov/study/NCT02599714","created_at":"2021-01-18T12:37:17.664Z","updated_at":"2024-07-02T16:34:37.661Z","phase":"Phase 1","brief_title":"Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer","source_id_and_acronym":"NCT02599714 - PASTOR","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 12/07/2015","start_date":" 12/07/2015","primary_txt":" Primary completion: 03/30/2018","primary_completion_date":" 03/30/2018","study_txt":" Completion: 11/23/2023","study_completion_date":" 11/23/2023","last_update_posted":"2024-06-06"},{"id":"1782eac1-bff9-41f2-9bc7-5e0ddfcda445","acronym":"","url":"https://clinicaltrials.gov/study/NCT06437574","created_at":"2024-05-31T20:35:39.012Z","updated_at":"2024-07-02T16:34:37.911Z","phase":"Phase 2","brief_title":"Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer","source_id_and_acronym":"NCT06437574","lead_sponsor":"Cedars-Sinai Medical Center","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • ezetimibe/simvastatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2024-06-05"},{"id":"92222cde-38f1-4798-9e7b-0b2b4361f314","acronym":"","url":"https://clinicaltrials.gov/study/NCT05436418","created_at":"2022-06-29T15:59:10.686Z","updated_at":"2024-07-02T16:34:38.201Z","phase":"Phase 1/2","brief_title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","source_id_and_acronym":"NCT05436418","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["IGH • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 06/25/2027","primary_completion_date":" 06/25/2027","study_txt":" Completion: 07/02/2027","study_completion_date":" 07/02/2027","last_update_posted":"2024-06-05"},{"id":"0300bd11-3c88-4727-a08a-0abd664e0d55","acronym":"","url":"https://clinicaltrials.gov/study/NCT05773326","created_at":"2023-03-17T14:02:34.285Z","updated_at":"2024-07-02T16:35:02.449Z","phase":"Phase 1","brief_title":"Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG","source_id_and_acronym":"NCT05773326","lead_sponsor":"Nader Sanai","biomarkers":" PIK3CA • PTEN • mTOR • PIK3R1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation","tags":["PIK3CA • PTEN • mTOR • PIK3R1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2024-05-21"},{"id":"6f199ca7-66c7-422b-8786-948a1a709536","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213678","created_at":"2021-01-18T15:51:26.276Z","updated_at":"2024-07-02T16:35:02.372Z","phase":"Phase 2","brief_title":"Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213678","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • TSC2 • TSC1","pipe":" | ","alterations":" PTEN expression • TSC1 mutation • TSC2 mutation","tags":["PTEN • TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression • TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-05-21"},{"id":"bd3903e4-47f8-44a5-a2e7-496b069f8567","acronym":"","url":"https://clinicaltrials.gov/study/NCT02208375","created_at":"2021-01-18T10:20:36.481Z","updated_at":"2024-07-02T16:35:02.701Z","phase":"Phase 1/2","brief_title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","source_id_and_acronym":"NCT02208375","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR • BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["ER • PGR • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 11/11/2014","start_date":" 11/11/2014","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-05-17"},{"id":"2e6bf495-dfa3-4ba8-b86c-4970f2d282c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01428973","created_at":"2021-01-18T05:54:04.661Z","updated_at":"2024-07-02T16:35:04.762Z","phase":"Phase 2","brief_title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","source_id_and_acronym":"NCT01428973","lead_sponsor":"University of Liege","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-09"},{"id":"8c91534d-fea7-416e-b7d1-5b8ca484c757","acronym":"","url":"https://clinicaltrials.gov/study/NCT03765983","created_at":"2021-01-18T18:38:07.887Z","updated_at":"2024-07-02T16:35:05.419Z","phase":"Phase 2","brief_title":"GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases","source_id_and_acronym":"NCT03765983","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • EIF4EBP1","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification","tags":["HER-2 • EIF4EBP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paxalisib (GDC-0084)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 02/11/2019","start_date":" 02/11/2019","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-05-07"},{"id":"7fd8451e-e40a-4b5b-98c2-c1a67ba94776","acronym":"","url":"https://clinicaltrials.gov/study/NCT04192981","created_at":"2021-01-18T20:26:03.024Z","updated_at":"2024-07-02T16:35:09.028Z","phase":"Phase 1","brief_title":"GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases","source_id_and_acronym":"NCT04192981","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3CG • PIK3CD • PIK3CB • INPP4B • AKT2 • INPP5D • PIK3C3 • PIK3R2 • PIK3R3","pipe":"","alterations":" ","tags":["PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3CG • PIK3CD • PIK3CB • INPP4B • AKT2 • INPP5D • PIK3C3 • PIK3R2 • PIK3R3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paxalisib (GDC-0084)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-17"},{"id":"7ce382c5-c733-46c1-a191-5c9b114e6676","acronym":"UNIRAD","url":"https://clinicaltrials.gov/study/NCT01805271","created_at":"2021-01-18T08:00:01.329Z","updated_at":"2024-07-02T16:35:10.322Z","phase":"Phase 3","brief_title":"Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy","source_id_and_acronym":"NCT01805271 - UNIRAD","lead_sponsor":"UNICANCER","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1278","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2024-04-10"},{"id":"b8db270b-31ec-42b3-ae0d-efec0f07af53","acronym":"CLEVER","url":"https://clinicaltrials.gov/study/NCT03032406","created_at":"2021-01-18T14:55:32.607Z","updated_at":"2024-07-02T16:35:15.139Z","phase":"Phase 2","brief_title":"CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer","source_id_and_acronym":"NCT03032406 - CLEVER","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" ER • ALK • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/23/2017","start_date":" 01/23/2017","primary_txt":" Primary completion: 05/17/2022","primary_completion_date":" 05/17/2022","study_txt":" Completion: 05/23/2025","study_completion_date":" 05/23/2025","last_update_posted":"2024-03-12"}]